Johnson & Johnson To Start Single-shot Vaccine Trials in India

US pharma giant Johnson & Johnson is reportedly in talks with the Indian government to begin a clinical trial of its single-shot COVID-19 vaccine. This news comes at a critical juncture in India’s fight against a rising tide of COVID cases nationwide.

Johnson & Johnson met with the Drugs Controller General of India (DCGI) to get approval for holding clinical trials in the country. The one-shot COVID vaccine developed by the healthcare company is currently adopted in the United States, the European Union and others including South Africa and Thailand.

A spokesperson for the Indian department of the company said, “We are in discussions with the Government of India with the objective of starting a bridging clinical study of our Janssen COVID-19 vaccine candidate in India, subject to local regulatory approvals.”

The DCGI has always stressed on the importance of bridging studies and had even refused Pfizer import licence for its messenger RNA vaccine.

Johnson & Johnson has also roped in Hyderabad-based Biological E as a manufacturer for its single-shot vaccines.

The vaccine could be a critical tool in India’s arsenal due to its proven track record in the US with a success rate of 66.3%.

The Indian government has currently approved two vaccines to be used for vaccination drives – the AstraZeneca-Oxford vaccine and a domestic variant from Bharat Biotech.

As several states in India are struggling to get their citizens vaccinated amidst growing concerns of vaccine shortage, the latest announcement by Johnson & Johnson should calm frayed nerves.

Top government sources confirmed the news in a statement saying, “Johnson & Johnson has sent a letter to the CDSCO (Central Drugs Standard Control Organisation) that they will very shortly apply for permission to conduct clinical bridging trials in India.”

A successful trial could see the vaccines being marketed in India which will relieve the burden on Serum Institute of India and Bharat Biotech, which are already struggling to increase production capacities.

Andrew s

Andrew has been in the online publishing industry. After receiving his degree in professional journalism from the Indian Institute of Journalism and New Media, he contributed to multiple websites as a freelance writer and feature editor. Mostly, Andrew tackles controversies and theories that lead to a specific conclusion that either debunk or justify a particular claim. Further, Andrew participates in social developments that aim to simplify every individual's way of life and fight for peace. He is the new Editor-in-Chief of Pressroom Today.

Published by
Andrew s

Recent Posts

Varanasi’s Blend of Tradition and Modernity: A Glimpse into the New Cricket Stadium

The stadium, situated in the heart of PM Modi's parliamentary constituency, aims to blend modern…

3 days ago

Akasa Air Faces Turmoil amid Pilot Resignations and Flight Cancellations

In a shocking turn of events, India's youngest airline, Akasa Air, has found itself in…

4 days ago

The Women’s Reservation Bill Takes Center Stage in the New Parliament

In a momentous move, the Indian Union government introduced the Constitution (One Hundred and Twenty-Eighth)…

5 days ago

India’s Asia Cup Dominance: A Legacy of Cricket Excellence

Cricket, often described as a religion in India, holds a special place in the hearts…

1 week ago

Rising Aspirations in PoK: A Call for Change and Reunification with India

PoK (Pakistan-Occupied-Kashmir) has been in turmoil for months now, with riots breaking out in several…

1 week ago

Rajat Khare, Venture capitalist, sees great potential in Singaporean Startup XRVision

September, 2018 Singapore: Boundary Holding, a European Fund, has invested in Singapore-based XRVision - a leading…

2 weeks ago